Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment

Catherine H. Choi, Brian P. Schoenfeld, Aaron J. Bell, Paul Hinchey, Maria Kollaros, Michael J. Gertner, Newton H. Woo, Michael R. Tranfaglia, Mark F. Bear, R. Suzanne Zukin, Thomas V. McDonald, Thomas A. Jongens, Sean M J McBride

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Here we examine the effects of chronic treatment of Fragile X mice in vivo with lithium or a group II mGluR antagonist on mGluR-LTD at CA1 synapses. We find that long-term lithium treatment initiated during development (5-6 weeks of age) and continued throughout the lifetime of the Fragile X mice until 9-11 months of age restores normal mGluR-LTD. Additionally, chronic short-term treatment beginning in adult Fragile X mice (8 weeks of age) with either lithium or an mGluR antagonist is also able to restore normal mGluR-LTD. Translating the findings of successful pharmacologic intervention from the Drosophila model into the mouse model of Fragile X syndrome is an important advance, in that this identifies and validates these targets as potential therapeutic interventions for the treatment of individuals afflicted with Fragile X syndrome.

Original languageEnglish (US)
Pages (from-to)106-119
Number of pages14
JournalBrain Research
Volume1380
DOIs
StatePublished - Mar 22 2011

Fingerprint

Fragile X Syndrome
Excitatory Amino Acid Antagonists
Metabotropic Glutamate Receptors
Neuronal Plasticity
Lithium
Pharmacology
Depression
Synapses
Drosophila
Hippocampus
Intellectual Disability
Genes

Keywords

  • Fragile X syndrome
  • Lithium
  • Long-term depression
  • LY341495
  • Metabotropic glutamate receptor

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment. / Choi, Catherine H.; Schoenfeld, Brian P.; Bell, Aaron J.; Hinchey, Paul; Kollaros, Maria; Gertner, Michael J.; Woo, Newton H.; Tranfaglia, Michael R.; Bear, Mark F.; Zukin, R. Suzanne; McDonald, Thomas V.; Jongens, Thomas A.; McBride, Sean M J.

In: Brain Research, Vol. 1380, 22.03.2011, p. 106-119.

Research output: Contribution to journalArticle

Choi, CH, Schoenfeld, BP, Bell, AJ, Hinchey, P, Kollaros, M, Gertner, MJ, Woo, NH, Tranfaglia, MR, Bear, MF, Zukin, RS, McDonald, TV, Jongens, TA & McBride, SMJ 2011, 'Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment', Brain Research, vol. 1380, pp. 106-119. https://doi.org/10.1016/j.brainres.2010.11.032
Choi, Catherine H. ; Schoenfeld, Brian P. ; Bell, Aaron J. ; Hinchey, Paul ; Kollaros, Maria ; Gertner, Michael J. ; Woo, Newton H. ; Tranfaglia, Michael R. ; Bear, Mark F. ; Zukin, R. Suzanne ; McDonald, Thomas V. ; Jongens, Thomas A. ; McBride, Sean M J. / Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment. In: Brain Research. 2011 ; Vol. 1380. pp. 106-119.
@article{c10681ebebee4388aa9fb3fbf88a80cf,
title = "Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment",
abstract = "Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Here we examine the effects of chronic treatment of Fragile X mice in vivo with lithium or a group II mGluR antagonist on mGluR-LTD at CA1 synapses. We find that long-term lithium treatment initiated during development (5-6 weeks of age) and continued throughout the lifetime of the Fragile X mice until 9-11 months of age restores normal mGluR-LTD. Additionally, chronic short-term treatment beginning in adult Fragile X mice (8 weeks of age) with either lithium or an mGluR antagonist is also able to restore normal mGluR-LTD. Translating the findings of successful pharmacologic intervention from the Drosophila model into the mouse model of Fragile X syndrome is an important advance, in that this identifies and validates these targets as potential therapeutic interventions for the treatment of individuals afflicted with Fragile X syndrome.",
keywords = "Fragile X syndrome, Lithium, Long-term depression, LY341495, Metabotropic glutamate receptor",
author = "Choi, {Catherine H.} and Schoenfeld, {Brian P.} and Bell, {Aaron J.} and Paul Hinchey and Maria Kollaros and Gertner, {Michael J.} and Woo, {Newton H.} and Tranfaglia, {Michael R.} and Bear, {Mark F.} and Zukin, {R. Suzanne} and McDonald, {Thomas V.} and Jongens, {Thomas A.} and McBride, {Sean M J}",
year = "2011",
month = "3",
day = "22",
doi = "10.1016/j.brainres.2010.11.032",
language = "English (US)",
volume = "1380",
pages = "106--119",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment

AU - Choi, Catherine H.

AU - Schoenfeld, Brian P.

AU - Bell, Aaron J.

AU - Hinchey, Paul

AU - Kollaros, Maria

AU - Gertner, Michael J.

AU - Woo, Newton H.

AU - Tranfaglia, Michael R.

AU - Bear, Mark F.

AU - Zukin, R. Suzanne

AU - McDonald, Thomas V.

AU - Jongens, Thomas A.

AU - McBride, Sean M J

PY - 2011/3/22

Y1 - 2011/3/22

N2 - Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Here we examine the effects of chronic treatment of Fragile X mice in vivo with lithium or a group II mGluR antagonist on mGluR-LTD at CA1 synapses. We find that long-term lithium treatment initiated during development (5-6 weeks of age) and continued throughout the lifetime of the Fragile X mice until 9-11 months of age restores normal mGluR-LTD. Additionally, chronic short-term treatment beginning in adult Fragile X mice (8 weeks of age) with either lithium or an mGluR antagonist is also able to restore normal mGluR-LTD. Translating the findings of successful pharmacologic intervention from the Drosophila model into the mouse model of Fragile X syndrome is an important advance, in that this identifies and validates these targets as potential therapeutic interventions for the treatment of individuals afflicted with Fragile X syndrome.

AB - Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Here we examine the effects of chronic treatment of Fragile X mice in vivo with lithium or a group II mGluR antagonist on mGluR-LTD at CA1 synapses. We find that long-term lithium treatment initiated during development (5-6 weeks of age) and continued throughout the lifetime of the Fragile X mice until 9-11 months of age restores normal mGluR-LTD. Additionally, chronic short-term treatment beginning in adult Fragile X mice (8 weeks of age) with either lithium or an mGluR antagonist is also able to restore normal mGluR-LTD. Translating the findings of successful pharmacologic intervention from the Drosophila model into the mouse model of Fragile X syndrome is an important advance, in that this identifies and validates these targets as potential therapeutic interventions for the treatment of individuals afflicted with Fragile X syndrome.

KW - Fragile X syndrome

KW - Lithium

KW - Long-term depression

KW - LY341495

KW - Metabotropic glutamate receptor

UR - http://www.scopus.com/inward/record.url?scp=79952315521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952315521&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2010.11.032

DO - 10.1016/j.brainres.2010.11.032

M3 - Article

C2 - 21078304

AN - SCOPUS:79952315521

VL - 1380

SP - 106

EP - 119

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -